|
1
|
Joshi SS and Badgwell BD: Current
treatment and recent progress in gastric cancer. CA Cancer J Clin.
71:264–279. 2021.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global Cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249.
2021.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Gong J, Chehrazi-Raffle A, Reddi S and
Salgia R: Development of PD-1 and PD-L1 inhibitors as a form of
cancer immunotherapy: A comprehensive review of registration trials
and future considerations. J Immunother Cancer. 6(8)2018.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Desrosiers R, Friderici K and Rottman F:
Identification of methylated nucleosides in messenger RNA from
Novikoff hepatoma cells. Proc Natl Acad Sci USA. 71:3971–3975.
1974.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Zaccara S, Ries RJ and Jaffrey SR:
Reading, writing and erasing mRNA methylation. Nat Rev Mol Cell
Biol. 20:608–624. 2019.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Wang L, Hui H, Agrawal K, Kang Y, Li N,
Tang R, Yuan J and Rana TM: m6A RNA methyltransferases
METTL3/14 regulate immune responses to anti-PD-1 therapy. EMBO J.
39(e104514)2020.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Huang H, Wang Y, Kandpal M, Zhao G,
Cardenas H, Ji Y, Chaparala A, Tanner EJ, Chen J, Davuluri RV and
Matei D: FTO-dependent N 6-methyladenosine modifications
inhibit ovarian cancer stem cell self-renewal by blocking cAMP
signaling. Cancer Res. 80:3200–3214. 2020.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Tang B, Yang Y, Kang M, Wang Y, Wang Y, Bi
Y, He S and Shimamoto F: m6A demethylase ALKBH5 inhibits
pancreatic cancer tumorigenesis by decreasing WIF-1 RNA methylation
and mediating Wnt signaling. Mol Cancer. 19(3)2020.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Xiao W, Adhikari S, Dahal U, Chen YS, Hao
YJ, Sun BF, Sun HY, Li A, Ping XL, Lai WY, et al: Nuclear
m6A reader YTHDC1 regulates mRNA splicing. Mol Cell.
61:507–519. 2016.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Wojtas MN, Pandey RR, Mendel M, Homolka D,
Sachidanandam R and Pillai RS: Regulation of m6A
transcripts by the 3'→5' RNA helicase YTHDC2 is essential for a
successful meiotic program in the mammalian germline. Mol Cell.
68:374–387.e12. 2017.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Zhang C, Huang S, Zhuang H, Ruan S, Zhou
Z, Huang K, Ji F, Ma Z, Hou B and He X: YTHDF2 promotes the liver
cancer stem cell phenotype and cancer metastasis by regulating OCT4
expression via m6A RNA methylation. Oncogene. 39:4507–4518.
2020.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Chang G, Shi L, Ye Y, Shi H, Zeng L,
Tiwary S, Huse JT, Huo L, Ma L, Ma Y, et al: YTHDF3 induces the
translation of m6A-enriched gene transcripts to promote breast
cancer brain metastasis. Cancer Cell. 38:857–871.e7.
2020.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Jia R, Chai P, Wang S, Sun B, Xu Y, Yang
Y, Ge S, Jia R, Yang YG and Fan X: m6A modification
suppresses ocular melanoma through modulating HINT2 mRNA
translation. Mol Cancer. 18(161)2019.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Liu T, Wei Q, Jin J, Luo Q, Liu Y, Yang Y,
Cheng C, Li L, Pi J, Si Y, et al: The m6A reader YTHDF1 promotes
ovarian cancer progression via augmenting EIF3C translation.
Nucleic Acids Res. 48:3816–3831. 2020.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Zhao X, Chen Y, Mao Q, Jiang X, Jiang W,
Chen J, Xu W, Zhong L and Sun X: Overexpression of YTHDF1 is
associated with poor prognosis in patients with hepatocellular
carcinoma. Cancer Biomark. 21:859–868. 2018.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Hu Y, Pan Q, Wang M, Ai X, Yan Y, Tian Y,
Jing Y, Tang P and Jiang J: m6A RNA methylation
regulator YTHDF1 correlated with immune microenvironment predicts
clinical outcomes and therapeutic efficacy in breast cancer. Front
Med (Lausanne). 8(667543)2021.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Wang Q, Zhang Q, Li Q and Zhang J and
Zhang J: Clinicopathological and immunological characterization of
RNA m6A methylation regulators in ovarian cancer. Mol
Genet Genomic Med. 9(e1547)2021.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Li T, Gu M, Deng A and Qian C: Increased
expression of YTHDF1 and HNRNPA2B1 as potent biomarkers for
melanoma: A systematic analysis. Cancer Cell Int.
20(239)2020.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Gao J, Aksoy BA, Dogrusoz U, Dresdner G,
Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, et al:
Integrative analysis of complex cancer genomics and clinical
profiles using the cBioPortal. Sci Signal. 6(pl1)2013.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Huang KK, Ramnarayanan K, Zhu F,
Srivastava S, Xu C, Tan ALK, Lee M, Tay S, Das K, Xing M, et al:
Genomic and epigenomic profiling of high-risk intestinal metaplasia
reveals molecular determinants of progression to gastric cancer.
Cancer Cell. 33:137–150.e5. 2018.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Wang K, Yuen ST, Xu J, Lee SP, Yan HH, Shi
ST, Siu HC, Deng S, Chu KM, Law S, et al: Whole-genome sequencing
and comprehensive molecular profiling identify new driver mutations
in gastric cancer. Nat Genet. 46:573–582. 2014.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Cancer Genome Atlas Research Network.
Comprehensive molecular characterization of gastric adenocarcinoma.
Nature. 513:202–209. 2014.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Kakiuchi M, Nishizawa T, Ueda H, Gotoh K,
Tanaka A, Hayashi A, Yamamoto S, Tatsuno K, Katoh H, Watanabe Y, et
al: Recurrent gain-of-function mutations of RHOA in diffuse-type
gastric carcinoma. Nat Genet. 46:583–587. 2014.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Wang K, Kan J, Yuen ST, Shi ST, Chu KM,
Law S, Chan TL, Kan Z, Chan AS, Tsui WY, et al: Exome sequencing
identifies frequent mutation of ARID1A in molecular subtypes of
gastric cancer. Nat Genet. 43:1219–1223. 2011.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Li T, Fan J, Wang B, Traugh N, Chen Q, Liu
JS, Li B and Liu XS: TIMER: A web server for comprehensive analysis
of tumor-infiltrating immune cells. Cancer Res. 77:e108–e110.
2017.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Chandrashekar DS, Bashel B, Balasubramanya
SAH, Creighton CJ, Ponce-Rodriguez I, Chakravarthi BVSK and
Varambally S: UALCAN: A portal for facilitating tumor subgroup gene
expression and survival analyses. Neoplasia. 19:649–658.
2017.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Ru B, Wong CN, Tong Y, Zhong JY, Zhong
SSW, Wu WC, Chu KC, Wong CY, Lau CY, Chen I, et al: TISIDB: An
integrated repository portal for tumor-immune system interactions.
Bioinformatics. 35:4200–4202. 2019.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Lánczky A and Győrffy B: Web-based
survival analysis tool tailored for medical research (KMplot):
Development and implementation. J Med Internet Res.
23(e27633)2021.PubMed/NCBI View
Article : Google Scholar
|
|
29
|
Tang Z, Li C, Kang B, Gao G, Li C and
Zhang Z: GEPIA: A web server for cancer and normal gene expression
profiling and interactive analyses. Nucleic Acids Res. 45:W98–W102.
2017.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Warde-Farley D, Donaldson SL, Comes O,
Zuberi K, Badrawi R, Chao P, Franz M, Grouios C, Kazi F, Lopes CT,
et al: The GeneMANIA prediction server: Biological network
integration for gene prioritization and predicting gene function.
Nucleic Acids Res. 38:W214–W220. 2010.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Patil A, Nakai K and Nakamura H:
HitPredict: A database of quality assessed protein-protein
interactions in nine species. Nucleic Acids Res. 39:D744–D749.
2011.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Vasaikar SV, Straub P, Wang J and Zhang B:
LinkedOmics: Analyzing multi-omics data within and across 32 cancer
types. Nucleic Acids Res. 46:D956–D963. 2018.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Ye J, Coulouris G, Zaretskaya I,
Cutcutache I, Rozen S and Madden TL: Primer-BLAST: A tool to design
target-specific primers for polymerase chain reaction. BMC
Bioinformatics. 13(134)2012.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408.
2001.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Li K, Zhang A, Li X, Zhang H and Zhao L:
Advances in clinical immunotherapy for gastric cancer. Biochim
Biophys Acta Rev Cancer. 1876(188615)2021.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Zhang C, Liu J, Xu D, Zhang T, Hu W and
Feng Z: Gain-of-function mutant p53 in cancer progression and
therapy. J Mol Cell Biol. 12:674–687. 2020.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Hanahan D: Hallmarks of cancer: New
dimensions. Cancer Discov. 12:31–46. 2022.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Pitt JM, Marabelle A, Eggermont A, Soria
JC, Kroemer G and Zitvogel L: Targeting the tumor microenvironment:
Removing obstruction to anticancer immune responses and
immunotherapy. Ann Oncol. 72:1482–1492. 2016.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Cui Y and Guo G: Immunomodulatory function
of the tumor suppressor p53 in host immune response and the tumor
microenvironment. Int J Mol Sci. 17(1942)2016.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Qi F, Li J, Qi Z, Zhang J, Zhou B, Yang B,
Qin W, Cui W and Xia J: Comprehensive metabolic profiling and
genome-wide analysis reveal therapeutic modalities for
hepatocellular carcinoma. Research (Wash D C).
6(0036)2023.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Zetrini AE, Lip H, Abbasi AZ, Alradwan I,
Ahmed T, He C, Henderson JT, Ranth AM and Wu X: Remodeling tumor
immune microenvironment by using polymer-lipid-manganese dioxide
nanoparticles with radiation therapy to boost immune response of
castration-resistant prostate cancer. Research (Wash D C).
6(0247)2023.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Duan X, Du H, Yuan M, Liu L, Liu R and Shi
J: Bioinformatics analysis of necroptosis-related lncRNAs and
immune infiltration, and prediction of the prognosis of patients
with esophageal carcinoma. Exp Ther Med. 26(331)2023.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Chen H, Yu Y, Yang M, Huang H, Ma S, Hu J,
Xi Z, Guo H, Yao G, Yang L, et al: YTHDF1 promotes breast cancer
progression by facilitating FOXM1 translation in an m6A-dependent
manner. Cell Biosci. 12(19)2022.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Pi J, Wang W, Ji M, Wang X, Wei X, Jin J,
Liu T, Qiang J, Qi Z, Li F, et al: YTHDF1 Promotes Gastric
Carcinogenesis by Controlling Translation of FZD7. Cancer
Res. 81:2651–2665. 2021.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Chen XY, Liang R, Yi YC, Fan HN, Chen M,
Zhang J and Zhu JS: The m6A reader YTHDF1 facilitates
the tumorigenesis and metastasis of gastric cancer via USP14
translation in an m6A-dependent manner. Front Cell Dev
Biol. 9(647702)2021.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Liu XS, Kui XY, Gao Y, Chen XQ, Zeng J,
Liu XY, Zhang Y, Zhang YH and Pei ZJ: Comprehensive analysis of
YTHDF1 immune infiltrates and ceRNA in human esophageal carcinoma.
Front Genet. 13(835265)2022.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Tsuchiya K, Yoshimura K, Inoue Y, Iwashita
Y, Yamada H, Kawase A, Watanabe T, Tanahashi M, Ogawa H, Funai K,
et al: YTHDF1 and YTHDF2 are associated with better patient
survival and an inflamed tumor-immune microenvironment in
non-small-cell lung cancer. OncoImmunology.
10(1962656)2021.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Han D, Liu J, Chen C, Dong L, Liu Y, Chang
R, Huang X, Liu Y, Wang J, Dougherty U, et al: Anti-tumour immunity
controlled through mRNA m6A methylation and YTHDF1 in
dendritic cells. Nature. 566:270–274. 2019.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Bai X, Wong CC, Pan Y, Chen H, Liu W, Zhai
J, Kang W, Shi Y, Yamamoto M, Tsukamoto T, et al: Loss of YTHDF1 in
gastric tumors restores sensitivity to antitumor immunity by
recruiting mature dendritic cells. J Immunother Cancer.
10(e003663)2022.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Shevach EM: Fatal attraction: Tumors
beckon regulatory T cells. Nat Med. 10:900–901. 2004.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Petersen RP, Campa MJ, Sperlazza J, Conlon
D, Joshi MB, Harpole DH Jr and Patz EF Jr: Tumor infiltrating
Foxp3+ regulatory T-cells are associated with recurrence in
pathologic stage I NSCLC patients. Cancer. 107:2866–2872.
2006.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Bates GJ, Fox SB, Han C, Leek RD, Garcia
JF, Harris AL and Banham AH: Quantification of regulatory T cells
enables the identification of high-risk breast cancer patients and
those at risk of late relapse. J Clin Oncol. 24:5373–5380.
2006.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Gao Q, Qiu SJ, Fan J, Zhou J, Wang XY,
Xiao YS, Xu Y, Li YW and Tang ZY: Intratumoral balance of
regulatory and cytotoxic T cells is associated with prognosis of
hepatocellular carcinoma after resection. J Clin Oncol.
25:2586–2593. 2007.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Perrone G, Ruffini PA, Catalano V, Spino
C, Santini D, Muretto P, Spoto C, Zingaretti C, Sisti V,
Alessandroni P, et al: Intratumoural FOXP3-positive regulatory T
cells are associated with adverse prognosis in radically resected
gastric cancer. Eur J Cancer. 44:1875–1882. 2008.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Georgiev P, Charbonnier LM and Chatila TA:
Regulatory T cells: The many faces of Foxp3. J Clin Immunol.
39:623–640. 2019.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Terranova-Barberio M, Pawlowska N, Dhawan
M, Moasser M, Chien AJ, Melisko ME, Rugo H, Rahimi R, Deal T, Daud
A, et al: Exhausted T cell signature predicts immunotherapy
response in ER-positive breast cancer. Nat Commun.
11(3584)2020.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Jin K, Cao Y, Gu Y, Fang H, Fei Y, Wang J,
Liu X, Lv K, He X, Lin C, et al: Poor clinical outcomes and
immunoevasive contexture in CXCL13+CD8+ T cells enriched gastric
cancer patients. Oncoimmunology. 10(1915560)2021.PubMed/NCBI View Article : Google Scholar
|
|
58
|
Zarour HM: Reversing T-cell dysfunction
and exhaustion in cancer. Clin Cancer Res. 22:1856–1864.
2016.PubMed/NCBI View Article : Google Scholar
|
|
59
|
Zhao T, Sun D, Zhao M, Lai Y, Liu Y and
Zhang Z: N6-methyladenosine mediates arsenite-induced
human keratinocyte transformation by suppressing p53 activation.
Environ Pollut. 259(113908)2020.PubMed/NCBI View Article : Google Scholar
|
|
60
|
Kwok CT, Marshall AD, Rasko JE and Wong
JJ: Genetic alterations of m6A regulators predict poorer
survival in acute myeloid leukemia. J Hematol Oncol.
10(39)2017.PubMed/NCBI View Article : Google Scholar
|
|
61
|
Xu A, Liu M, Huang MF, Zhang Y, Hu R,
Gingold JA, Liu Y, Zhu D, Chien CS, Wang WC, et al: Rewired
m6A epitranscriptomic networks link mutant p53 to
neoplastic transformation. Nat Commun. 14(1694)2023.PubMed/NCBI View Article : Google Scholar
|
|
62
|
Hassin O and Oren M: Drugging p53 in
cancer: One protein, many targets. Nat Rev Drug Discov. 22:127–144.
2023.PubMed/NCBI View Article : Google Scholar
|
|
63
|
Zeng Y and Jin RU: Molecular pathogenesis,
targeted therapies, and future perspectives for gastric cancer.
Semin Cancer Biol. 86:566–582. 2022.PubMed/NCBI View Article : Google Scholar
|
